Daxor (DXR) Corporation announces FDA 510(k) clearance for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer, BVA. The new Daxor BVA device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR: